Amgen’s trial brings new hope for IgG4-RD patients
Inebilizumab shows sound efficacy in landmark research
Read More
Tag: Inebilizumab
AstraZeneca spins out new firm Viela Bio
AstraZeneca’s biologics research and development arm MedImmune has spun out six molecules from its early-stage inflammation and autoimmunity programmes into new independent biotech Viela Bio.
Read More
AZ’ neuromyelitis drug picks up Orphan status in EU
European regulators have awarded AstraZeneca’s inebilizumab (formerly MEDI-551) Orphan status for the treatment of neuromyelitis optica spectrum disorder (NMOSD), opening the door to certain development and market exclusivity benefits.
Read More
